CLINICAL TRIALS PROFILE FOR ASFOTASE ALFA
✉ Email this page to a colleague
All Clinical Trials for asfotase alfa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01163149 ↗ | Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) | Completed | Alexion Pharma GmbH | Phase 2 | 2010-06-01 | This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study was to test the safety and efficacy of two doses of the study drug called asfotase alfa as compared to a control group to see effects on adolescents and adults with HPP. |
| NCT01163149 ↗ | Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) | Completed | Alexion Pharmaceuticals | Phase 2 | 2010-06-01 | This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study was to test the safety and efficacy of two doses of the study drug called asfotase alfa as compared to a control group to see effects on adolescents and adults with HPP. |
| NCT01176266 ↗ | Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) | Completed | Alexion Pharma GmbH | Phase 2/Phase 3 | 2010-07-01 | This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study was to test the safety and efficacy of a study drug called asfotase alfa (human recombinant tissue non-specific alkaline phosphate fusion protein) to see what effects it has on patients 5 years of age or less with HPP. |
| NCT01176266 ↗ | Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) | Completed | Alexion Pharmaceuticals | Phase 2/Phase 3 | 2010-07-01 | This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study was to test the safety and efficacy of a study drug called asfotase alfa (human recombinant tissue non-specific alkaline phosphate fusion protein) to see what effects it has on patients 5 years of age or less with HPP. |
| NCT02456038 ↗ | Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP) | Completed | Osaka University Graduate School of Medicine | Phase 2 | 2014-08-01 | The aim of this study is to assess safety and efficacy of Asfotase Alfa (ALXN1215) in patients with hypophosphatasia |
| NCT02456038 ↗ | Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP) | Completed | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Phase 2 | 2014-08-01 | The aim of this study is to assess safety and efficacy of Asfotase Alfa (ALXN1215) in patients with hypophosphatasia |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for asfotase alfa
Condition Name
Clinical Trial Locations for asfotase alfa
Trials by Country
Clinical Trial Progress for asfotase alfa
Clinical Trial Phase
Clinical Trial Sponsors for asfotase alfa
Sponsor Name
